Keros Therapeutics KROS
NASDAQ KROS
$9.54 +0.21 (+2.25%)
At close: Nov 11, 2026 · 4:00 PM EST

Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)

Updated

Keros Therapeutics (KROS) posted Preferred Stock Liabilities of $75.72 million for Q1 2020, up 279.7% from $19.94 million a year earlier and up 279.7% from the prior quarter.

Analysis

Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

At the end of FY2019, Keros Therapeutics' Preferred Stock Liabilities came in at $19.94 million.

  • According to Business Quant data, Preferred Stock Liabilities for the three prior quarters was $19.94 million (Q4 2019), $19.94 million (Q3 2019) and $19.94 million (Q2 2019).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Keros Therapeutics 185.02 Mn -900.96 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 75.72 Mn
Dec 31, 2019 19.94 Mn
Sep 30, 2019 19.94 Mn
Jun 30, 2019 19.94 Mn
Mar 31, 2019 19.94 Mn
API Access

Keros Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=KROS&period=max&api_key=YOUR_API_KEY